Arcutis Biotherapeutics, Inc. (ARQT)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$35.1M
Cash & Equivalents
$2.2M
Quarterly Burn Rate
$2,646M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
ROFLUMILAST
ZORYVE 		APPROVED Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis Eczema, Chronic Hand Eczema, Chronic Plaque Psoriasis, Eczema, Hidradenitis Suppurativa, ITCH, Non-segmental Vitiligo, Plaque Psoriasis, Psoriasis, Scalp Psoriasis, Seborrheic Dermatitis, Vitiligo

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07105254 An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patien... PHASE2 Recruiting 20

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ARQT.

SEC EDGAR Filings

All SEC filings for Arcutis Biotherapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.